Strait & Sound Wealth Management LLC Acquires New Stake in Regeneron Pharmaceuticals, Inc. $REGN

Strait & Sound Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 607 shares of the biopharmaceutical company’s stock, valued at approximately $319,000.

Other large investors have also made changes to their positions in the company. Activest Wealth Management boosted its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $27,000. Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $27,000. Colonial Trust Advisors acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $32,000. Finally, SouthState Corp boosted its stake in shares of Regeneron Pharmaceuticals by 550.0% during the first quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 44 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the topic of several recent analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Saturday. Guggenheim increased their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. UBS Group reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Argus downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 30th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $802.35.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $577.95 on Friday. The stock’s 50-day moving average is $576.32 and its 200-day moving average is $562.62. The company has a market cap of $61.26 billion, a price-to-earnings ratio of 14.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $943.83.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the business posted $11.56 EPS. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.